Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Ruderman

Showing results (61-70 of 79) with videos related to

Pageof 8
Sort By:
American Journal of Ophthalmology|July 15, 1992
Apraclonidine and argon laser trabeculoplastyP C Holmwood, R D Chase, T Krupin, et al.
Arthritis Care & Research|April 23, 2019
Patient and Rheumatologist Perspectives Regarding Challenges to Achieving Optimal Disease Control in Rheumatoid ArthritisJustin K Owensby, Lang Chen, Ronan O'Beirne, et al.
ACR Open Rheumatology|December 28, 2021
Evaluation of an Intervention to Support Patient-Rheumatologist Conversations About Escalating Treatment in Patients with Rheumatoid Arthritis: A Proof-of-Principle StudyMaria I Danila, Lang Chen, Eric M Ruderman, et al.
Arthritis and Rheumatism|June 1, 1996
N-[4-hydroxyphenyl] retinamide in rheumatoid arthritis: a pilot studyE M Gravallese, M L Handel, J Coblyn, et al.
Rheumatology (Oxford, England)|December 5, 2021
Upadacitinib as monotherapy and in combination with non-biologic disease-modifying antirheumatic drugs for psoriatic arthritisPeter Nash, Pascal Richette, Laure Gossec, et al.
European Journal of Immunology|February 4, 2009
The CDK domain of p21 is a suppressor of IL-1beta-mediated inflammation in activated macrophagesJohn C Scatizzi, Melissa Mavers, Jack Hutcheson, et al.
Arthritis and Rheumatism|October 4, 2005
Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trialPhilip J Mease, Dafna D Gladman, Christopher T Ritchlin, et al.
Rheumatology and Therapy|December 31, 2021
Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 TrialsGerd R Burmester, Kevin Winthrop, Ricardo Blanco, et al.
Inflammatory Bowel Diseases|August 31, 2021
Low-dose Methotrexate Therapy Does Not Affect Semen Parameters and Sperm DNAAnne Grosen, Emanuelle Bellaguarda, Jacob Nersting, et al.
Arthritis Care & Research|May 26, 2017
Cluster-Randomized Trial of a Behavioral Intervention to Incorporate a Treat-to-Target Approach to Care of US Patients With Rheumatoid ArthritisLeslie R Harrold, George W Reed, Ani John, et al.
Pageof 8

Showing results (61-70 of 79) with videos related to

Sort By:
Pageof 8
American Journal of Ophthalmology|July 15, 1992
Apraclonidine and argon laser trabeculoplastyP C Holmwood, R D Chase, T Krupin, et al.
Arthritis Care & Research|April 23, 2019
Patient and Rheumatologist Perspectives Regarding Challenges to Achieving Optimal Disease Control in Rheumatoid ArthritisJustin K Owensby, Lang Chen, Ronan O'Beirne, et al.
ACR Open Rheumatology|December 28, 2021
Evaluation of an Intervention to Support Patient-Rheumatologist Conversations About Escalating Treatment in Patients with Rheumatoid Arthritis: A Proof-of-Principle StudyMaria I Danila, Lang Chen, Eric M Ruderman, et al.
Arthritis and Rheumatism|June 1, 1996
N-[4-hydroxyphenyl] retinamide in rheumatoid arthritis: a pilot studyE M Gravallese, M L Handel, J Coblyn, et al.
Rheumatology (Oxford, England)|December 5, 2021
Upadacitinib as monotherapy and in combination with non-biologic disease-modifying antirheumatic drugs for psoriatic arthritisPeter Nash, Pascal Richette, Laure Gossec, et al.
European Journal of Immunology|February 4, 2009
The CDK domain of p21 is a suppressor of IL-1beta-mediated inflammation in activated macrophagesJohn C Scatizzi, Melissa Mavers, Jack Hutcheson, et al.
Arthritis and Rheumatism|October 4, 2005
Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trialPhilip J Mease, Dafna D Gladman, Christopher T Ritchlin, et al.
Rheumatology and Therapy|December 31, 2021
Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 TrialsGerd R Burmester, Kevin Winthrop, Ricardo Blanco, et al.
Inflammatory Bowel Diseases|August 31, 2021
Low-dose Methotrexate Therapy Does Not Affect Semen Parameters and Sperm DNAAnne Grosen, Emanuelle Bellaguarda, Jacob Nersting, et al.
Arthritis Care & Research|May 26, 2017
Cluster-Randomized Trial of a Behavioral Intervention to Incorporate a Treat-to-Target Approach to Care of US Patients With Rheumatoid ArthritisLeslie R Harrold, George W Reed, Ani John, et al.
Pageof 8